CRISPR technology in response to COVID-19 and beyond

Total
0
Shares
Dna Network Research Chemistry Medical Biology

Franco Goytia is a serial entrepreneur; currently the CEO of Caspr Biotech, a startup he co-founded at the age of 23. Caspr is using Crispr technology to make better and more accessible molecular diagnostics solutions. Prior to this, at the age of 21, he founded Ando a B2B last-mile logistics solution in LATAM. He did this while studying Economics at Universidad de San Andres in Argentina. Ando was acquired by Moova in 2018. Some of his notable achievements include being selected for the US Dept. State Young Leaders Initiative (YLAI), being an alumni from the Westerwelle Foundation as a Young Founders and having participated of the Indie Bio acceleration program for biotech entrepreneurs in SF.

In the next years there is probably going to be a shift towards biotech and I think that biotech within Argentina, is set to become one of the strongest ecosytems in Latin America

Franco Goytia

On this episode, you’ll learn:

  1. What is CRISPR and what can it do? [2:20]
  2. How has the COVID-19 fallout affected the Buenos Aires startup ecosystem? [14:00]
  3. How was CASPR originally using CRISPR to combate the Zika Virus?[18:15]

Recorded in partnership with

PeaceTech Lab works to reduce violent conflict using technology, media, and data to accelerate and scale peacebuilding efforts. An independent nonprofit, the Lab brings together engineers and activists, MBAs and conflict experts, social scientists, data scientists, and other innovators to put the right tools in the right hands to build peace.

Subscribe on your favorite podcast app!

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign Up for Our Newsletters

Get notified of the best deals on our WordPress themes.

You May Also Like